Alpelisib (PI3Kα inhibitor) in combination with fulvestrant (selective estrogen receptor degrader) is a treatment option for patients with estrogen-receptor positive (ER+)/HER2-negative advanced BC, previously exposed to endocrine therapy and with mutations in PIK3CA/PI3Kα [10]. This evidence concerns the gene PIK3CA and breast cancer.